Avita Medical Q3 net loss narrows 53% to $6.22 million; revenue rises 53% to $26.1 million
RCEL•Avita Medical's third-quarter 2026 net loss narrowed 53% year over year to $6.22 million, while revenue rose 53% to $26.1 million. The company raised full-year revenue guidance to $92 million–$94 million and said fourth-quarter cash flow breakeven remains expected.
1. Quarterly results
Third-quarter 2026 revenue increased 53% year over year to $26.1 million, and gross margin rose to 84%. Net loss narrowed 53% to $6.22 million.
2. Guidance and liquidity
Avita Medical raised its full-year 2026 revenue guidance to $92 million–$94 million and said it continues to expect cash flow breakeven in the fourth quarter. A $10 million credit facility draw after quarter-end strengthened liquidity; improved operating performance and liquidity alleviated going-concern doubts.
3. Medicare payment changes
Medicare finalized national physician payment values and simplified billing codes for RECELL procedures, effective January 1, 2027.
